Not financial advice. Focused on compelling growth opportunities for high-alpha market returns in multiple sectors.

Joined August 2023
2,192 Photos and videos
Pinned Post
TrendSpider 4th of July Giveaway πŸ‘€ Win 1 month free TrendSpider Premium access ($137 value). I’m choosing 2 lucky winners! TrendSpider is an all-in-one market research and trading platform. Scan for trade opportunities, analyze charts and market data, run no-code backtests, and automate your workflow with Sidekick AI. How to enter: βœ… Like βœ… Repost βœ… Drop your favorite ticker in the comments Giveaway entries close July 7th @ midnight πŸ‡ΊπŸ‡Έ Save up to 42% and get $355 in free upgrades. trendspider.com?_go=jkeynes
9
6
12
10,597
$CRWV $NBIS πŸ‘€ facts
πŸ‡ΊπŸ‡Έ AMERICAN DATA CENTERS πŸ‡ΊπŸ‡Έ Excellent piece in FT by my friend @joshzoff arguing that the US can't treat data centers like we treated rare earths, and that data centers are a great way to finance development of a bunch of other advanced technologies (strong agree).
1
1
59
16,236
$CRWV at $81.75 is the screaming buy in AI infrastructure right now πŸ”₯πŸ”₯ It is also the leader in U.S. Sovereign AI πŸ‡ΊπŸ‡Έ Don't lack the "situational awareness" to see it. Here's the bull thesis in a nutshellπŸ‘€ Here's the number that should stop you cold: CoreWeave will exit 2027 at a $30B revenue run-rate, and more than 75% of it is already contracted. Today's entire market cap is ~$44.6B. You are paying roughly 1.5x market-cap for signed, take-or-pay contracts on six times its 2025 revenue, eighteen months out. Those are locked commitments. And you're buying it on sale. A $99.4B contracted backlog against that ~$44.6B cap is ~0.45x market-cap-to-backlog. Revenue grew 112% YoY last quarter. The market handed you a big two-day drop on a Meta headline. This is the fastest-scaling AI cloud in history. Revenue went from roughly $16M in 2022 to $1.92B in 2024 to $5.13B in 2025, and management guides to $12–13B this year on the way to a $30B run-rate exiting 2027. That is a company going from essentially nothing to a $30B revenue pace in about five years. It signed more than $40B of new bookings in a single quarter and pushed backlog to $99.4B. No infrastructure company has ever ramped contracted revenue at that dollar pace. Power is the real bottleneck in AI, and CoreWeave has already locked up years of it. They hold ~3.5 GW of power under contract and are converting it to live capacity as fast as they can build, more than doubling active power to 1.7 GW by year-end 2026 and scaling toward 8 GW by 2030. Every gigawatt they energize is already spoken for, so growth here comes down to execution on power they've already secured. First self-build sites are coming online now to capture even more of the economics. CoreWeave is first to market on GB200, GB300, and Vera Rubin. The only Platinum ClusterMAX provider, two rounds running. NVIDIA put $2B into the stock at $87.20 last quarter, so today you're buying it cheaper than NVIDIA did. Rosenblatt's John McPeake reiterated a $250 target and called this exact selloff a buying opportunity, and Roth called the neocloud selloff overdone. The single-customer risk that shadowed the IPO is gone. Microsoft was ~62% of revenue in 2024. Today CoreWeave counts nine of the top ten AI model developers as customers, and management says no single one will exceed roughly 35% of contracted revenue. Look at the roster: OpenAI (~$22.4B), Meta (~$35B through 2032), Anthropic (multi-year Claude deal), plus Microsoft, Mistral, Cohere, and IBM. Then it expanded well beyond the AI labs. Jane Street signed a $6B compute deal and put $1B of equity in at $109 a share, pulling in quant finance, with financial-services backlog now near $10B. And NVIDIA backstopped $6.3B of capacity through 2032 on top of its equity stake. When nine of the ten companies building frontier AI all pay you rent, you own the toll road. And the demand is the sticky kind. Inference is now over 50% of consumed compute, recurring production workloads that repeat every day. That's why pricing rose quarter-over-quarter across A100, H100, H200, and L40S. Rising prices in a supposedly commoditized market prove real pricing power. CoreWeave has it. 2027 is where the operating leverage shows. Management called Q1 the margin trough. Margins expand every quarter from here, exiting 2026 at low double-digit operating margins with $18–19B of run-rate revenue on the way to $30B . This is the year the earning power becomes visible on the page. Then the moat nobody's pricing: sovereign AI. $CRWV stood up CoreWeave Federal for U.S. government and the Defense Industrial Base, joined the DOE's Genesis Mission for national security, and is pursuing FedRAMP authorization. Classified and defense compute has to run on U.S. soil, inside U.S. jurisdiction. Washington will keep that work with the domestic leader, and a Netherlands-domiciled company built out of Russian-origin Yandex sits outside that door. And the debt everyone frets about is the most misunderstood part of the story. Every big loan is backed by a signed take-or-pay contract and the GPUs themselves. The $8.5B facility earned the first investment-grade rating of its kind, with no maturities until 2029, and interest already covered more than 2x on adjusted EBITDA this early in the build. The same contracts that fill the backlog service the debt. Cost of capital keeps falling, S&P moved the outlook to positive, and CoreWeave just joined the Nasdaq-100. So here is the real question, and it decides everything. If you do not believe AI is a generational shift, if you think the demand is a mirage and the models are near their ceiling, then you should not own any neocloud! Zero. Not CoreWeave, not $NBIS, not one of them. This whole sector rests on one conviction: that AI keeps getting more capable and the world keeps needing more compute to run it. And the biggest companies on earth are voting with real money. The Mag 7 and the hyperscalers are pouring hundreds of billions of their own cash into AI infrastructure, $Meta alone budgeting $115 to $135 billion in capex this year. Leopold Aschenbrenner's Situational Awareness makes the case for where this leads (he hardly needs a citation but here: situational-awareness.ai/). He traces the same scaling that carried models from preschooler to smart high-schooler in four years and argues it points to AGI by around 2027. His more staggering claim comes next. Once AI can do AI research, hundreds of millions of those systems could automate the work themselves, compressing a decade of algorithmic progress into a single year and running at many times human speed. That feedback loop, smarter AI building smarter AI, is the intelligence explosion, and it turns compute into the most strategic resource on the planet. He calls it the most extraordinary techno-capital acceleration ever set in motion, with trillions flowing into GPUs, data centers, and power before the decade is out, and a fierce scramble to lock up every power contract still available. That scramble is happening right now, and CoreWeave is winning its share of it. It's THE primier United States Neocloud, Whether the timeline lands in 2027 or later, the direction is set, and the entire race runs on one thing: compute. Every model, every breakthrough, every step toward that future gets trained and served on infrastructure someone has to own and operate. I believe the demand is real, I believe it is durable, and I believe CoreWeave is the leading entirely U.S.-based company building that infrastructure at the frontier, first to every new chip, with the power and the contracts already locked. If you share that conviction, you want the leader. This is it. $CRWV 30B contracted for 2027. ~3.5 GW power under contract, converting fast. $99.4B backlog. Nine of the top ten AI labs. Sovereign moat. NVIDIA in at $87.20. Priced at discount. Long and sized for it. And I plan to HODL to realize a very minimal 5-10x. I think as a growth story in the Nasdaq 100, with the success of the AI industry, CoreWeave is an obvious winner and a company of very great importanceπŸš€
$CRWV πŸ”₯πŸ”₯πŸ”₯which is why I loaded the friggin boat on CoreWeave…. The easiest no brainer buy I remember in a while just sitting there Thursday in the low 80s!
18
22
218
33,142
$IREN πŸ‘€ this article worth a look
$IREN's Executive Compensation My full take on $IREN's controversial RSU package is now live on Substack for FREE. While this topic has been discussed to death already, I believe my piece brings some unique perspectives to the table and might shift a few opinions. I'm genuinely curious to hear your feedback in the comments! If you don't already have a Substack account, it just takes about 2 minutes to set up. Very user-friendly platform. Cheers! agrippa.investments/p/irens-…
8
6
191
52,467
The bear narrative is nothing more than a grift.
The AI narrative is nothing more than mass addiction.
20
4,979
Anyone who is like β€œthe data is not valuable” is talking nonsense. If it’s not valuable then why is the growth in those segments so insane. Big pharma are paying 9 figure deals and renewing them to get the data **Tempus ($TEM) Q1 2026:** Revenue **$348.1M** ( 36% YoY) - Diagnostics: **$261.1M** ( 35%) - Data & Applications (AI/data licensing): **$87M** ( 40.5%), Insights 44% **FY 2026 guidance raised:** $1.59–1.60B revenue (~25% growth) ~$65M Adj. EBITDA. πŸ”₯πŸ”₯πŸ”₯πŸ”₯
2
4
1,755
Really there is no catch here, comment on the post below and I’ll pick two winners for free 1 month TrendSpider accounts. Try it, you will like it. Winners will get the accounts directly from TrendSpider, not me! Special for my followers! Happy 4thπŸ‡ΊπŸ‡ΈπŸ‡ΊπŸ‡ΈπŸ‡ΊπŸ‡Έ
TrendSpider 4th of July Giveaway πŸ‘€ Win 1 month free TrendSpider Premium access ($137 value). I’m choosing 2 lucky winners! TrendSpider is an all-in-one market research and trading platform. Scan for trade opportunities, analyze charts and market data, run no-code backtests, and automate your workflow with Sidekick AI. How to enter: βœ… Like βœ… Repost βœ… Drop your favorite ticker in the comments Giveaway entries close July 7th @ midnight πŸ‡ΊπŸ‡Έ Save up to 42% and get $355 in free upgrades. trendspider.com?_go=jkeynes
2
3,541
J Keynes reposted
I still think $ASTS is undervalued... They launched their largest commercial satellites in LEO last month, FCC just approved direct phone-to-satellite services, and Japan handed them $926M... $SPCX rotation really dragged down the whole sector, but it seems like we're near the bottom? From a technical aspect, looks like we're about to get another buy-signal on Startup.io indicators as well, with 3 BDs already confirmed.
Nice to see capital rotate back to the rest of the sector... wasn't kidding when I said $ASTS / $RKLB was being oversold. Bounced perfectly off green support as well... πŸ‘€
40
41
424
101,583
$CRWV πŸ”₯πŸ”₯πŸ”₯which is why I loaded the friggin boat on CoreWeave…. The easiest no brainer buy I remember in a while just sitting there Thursday in the low 80s!
Is the AI infrastructure trade running out of steam? JPMorgan: Data Center Watch report says not even close. Worth bookmarking if you're tracking the AI capex debate. Token usage, GPU leasing rates, and DRAM prices continue to rise. JPM noted in its latest 'Data Center Watch' report that large model usage continues to expand rapidly, token spending has reaccelerated, GPU leasing prices in the non-hyperscale cloud market are still rising, and DRAM spot prices remain strong. > LLM token : June volume 70% MoM (vs May's 33%, April's 5%). YoY growth hit 20x, above May's 12x and April's 15x. Token spending also rebounded, 70% MoM and 16x YoY, snapping the prior two months' slowdown. > Unit economics: Token usage and revenue are diverging. Falling model prices haven't dented market revenue - price erosion is slowing while usage growth outruns the cuts. This is the number that decides if AI commercialization actually works. > Country wars: US models (OpenAI, Anthropic, Google, xAI) fell to 35% of OpenRouter token share, down from 46% in May and 56% in April - even as their volume grew 30% MoM and 8x YoY. Chinese/low-cost models (DeepSeek, MiniMax, MiMo, GLM) are eating share in cost-sensitive use cases: dev workflows, startups, agent coding. > Rental prices: A100 at $1.63/GPU-hour ( 6.3% MoM, 5th straight monthly rise). H100 at $2.72 ( 3.7% MoM, 7th straight month up). B200 at $5.33 ( 2.7% MoM). > Memory: AI server DRAM demand is pulling supply from conventional DRAM. Three straight months of modest price declines suggest NAND tightness is easing - but prices are still up 5x YoY, so the industry hasn't hit supply abundance yet. Which number surprises you more: token growth reaccelerating to 20x YoY, or GPU rental rates still climbing after 5-7 straight monthly increases? Repost this if you're tired of the "AI capex is slowing" take this report has the actual numbers on it.
9
10
151
56,695
$TEM Tempus, Frontier Labs, and the Ontology Problem: Why Frontier Labs Need Tempus more than Tempus Needs Them Great thoughts here. Lefkofsky is not going to give away the crown jewels for free or for less than they’re worth. He has raised the frontier lab conversation several times and pointed out that those labs lack the data and integration $TEM has. Couple that with what Alex Karp said on CNBC last week. Dump your data into frontier lab models willy-nilly under a partnership and they can steal your data, steal your alpha, and steal your business. Look at Figma. If a deal happens, it gets structured the right way. It does not become an arrangement that generates a press release while handing a frontier lab a path to erode the moat. Building our own foundation models tells you @lefkofsky already thinks like Karp. He knows he has to own the alpha, build his own models, and protect the value that lives in the unique data and integrations, and above all in what $PLTR calls the ontology. The fact that very large big pharma partners are involved in training those foundation models, with their own weights, shows you they understand this too. They are not going to rent the intelligence or let it get stolen. They are owning it. Ontology is Karp’s idea, and it is apt here. An ontology is the layer that maps raw data onto real entities and the relationships between them, so a model reasons over patients, tumors, variants, therapies, and outcomes instead of disconnected rows in a table. Palantir built its worth on owning that semantic layer across defense and enterprise. Tempus owns the ontology of precision medicine. It is building the same structure for oncology, where a molecular profile links to a clinical history links to a treatment response, and that web of connections is the thing a frontier lab cannot scrape or replicate. That is what eventually sends the valuation to the stratosphere. Slowly it is becoming clear that frontier labs are not the whole game, as impressive as GPT and Claude are.
TLDR, I wouldn't buy it either unless its supported by population level real data sets like Tempus has. If one AI frontier lab goes around Tempus, Tempus can partner with another AI lab and combined, they will bury the competition. That said... At the JPM conf in January Lefkofsky mentioned they were considering the possibility of partnering on a consumer facing app. I think it was at JPM. If I remember correctly, I think he was implying or saying directly that an app like that would require immense consumer facing resources like a call center or something. Overall on the front of partnering with a frontier lab, I think access to Tempus' data would greatly advantage one over the other. It took time to get big pharma partners to sign a strategic partnership. Eric has said those came historically from smaller deals that grew into bigger deals due volume discounts. I would guess theres some game theory here that says its time to hold the line and now wait only big partnerships whether pharma or frontier lab. I would also guess (and these are all guesses) that the stakes are higher with giving an AI lab incremental access. In the old days of Tesla AI day presentations they did a great job of generating synthetic data to run edge case simulations for FSD. My guess is Tempus is very conscientious of that slippery slope. All the frontier labs, really everyone in AI, are obsessed w curing cancer. My underlying assumption is getting a deal done will take time because a deal like this can make a step function in the experience of getting diagnosed with cancer and how both patients and care providers treat cancer. Throw MRD and $PSNL technology in there too and its game, set and match. So much at stake means to me a deal will need a lot of consideration. Is it with one lab or non-exclusive? Is there a pharma and/or provider partner involved? I believe Lefkofsky and Fukushima are the right people at the table to play this hand out. Any product that isn't supported by real data I wouldn't buy either. Genomic and multimodal data has too much search space and the decisions being considered are a lot more consequential than a fender bender.
5
4
58
11,603
$TEM interesting πŸ‘€
TLDR, I wouldn't buy it either unless its supported by population level real data sets like Tempus has. If one AI frontier lab goes around Tempus, Tempus can partner with another AI lab and combined, they will bury the competition. That said... At the JPM conf in January Lefkofsky mentioned they were considering the possibility of partnering on a consumer facing app. I think it was at JPM. If I remember correctly, I think he was implying or saying directly that an app like that would require immense consumer facing resources like a call center or something. Overall on the front of partnering with a frontier lab, I think access to Tempus' data would greatly advantage one over the other. It took time to get big pharma partners to sign a strategic partnership. Eric has said those came historically from smaller deals that grew into bigger deals due volume discounts. I would guess theres some game theory here that says its time to hold the line and now wait only big partnerships whether pharma or frontier lab. I would also guess (and these are all guesses) that the stakes are higher with giving an AI lab incremental access. In the old days of Tesla AI day presentations they did a great job of generating synthetic data to run edge case simulations for FSD. My guess is Tempus is very conscientious of that slippery slope. All the frontier labs, really everyone in AI, are obsessed w curing cancer. My underlying assumption is getting a deal done will take time because a deal like this can make a step function in the experience of getting diagnosed with cancer and how both patients and care providers treat cancer. Throw MRD and $PSNL technology in there too and its game, set and match. So much at stake means to me a deal will need a lot of consideration. Is it with one lab or non-exclusive? Is there a pharma and/or provider partner involved? I believe Lefkofsky and Fukushima are the right people at the table to play this hand out. Any product that isn't supported by real data I wouldn't buy either. Genomic and multimodal data has too much search space and the decisions being considered are a lot more consequential than a fender bender.
1
17
8,628
J Keynes reposted
TrendSpider 4th of July Giveaway πŸ‘€ Win 1 month free TrendSpider Premium access ($137 value). I’m choosing 2 lucky winners! TrendSpider is an all-in-one market research and trading platform. Scan for trade opportunities, analyze charts and market data, run no-code backtests, and automate your workflow with Sidekick AI. How to enter: βœ… Like βœ… Repost βœ… Drop your favorite ticker in the comments Giveaway entries close July 7th @ midnight πŸ‡ΊπŸ‡Έ Save up to 42% and get $355 in free upgrades. trendspider.com?_go=jkeynes
9
6
12
10,597
$ASTS $SNDK πŸš€ Yes.
24
39
766
81,122